CompletedPhase 2NCT01730950
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Studying Gliosarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- Christina Tsien, MDWashington University School of Medicine
- Intervention
- bevacizumab(biological)
- Enrollment
- 182 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2022
Study locations (30)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Arizona Oncology Services Foundation, Phoenix, Arizona, United States
- Arizona Oncology-Deer Valley Center, Phoenix, Arizona, United States
- John Muir Medical Center, Walnut Creek, California, United States
- Yale University, New Haven, Connecticut, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- Queen's Medical Center, Honolulu, Hawaii, United States
- Radiation Oncology Associates PC, Fort Wayne, Indiana, United States
- IU Health Methodist Hospital, Indianapolis, Indiana, United States
- Memorial Hospital of South Bend, South Bend, Indiana, United States
- Norton Health Care Pavilion - Downtown, Louisville, Kentucky, United States
- Maine Medical Center- Scarborough Campus, Scarborough, Maine, United States
- Lowell General Hospital, Lowell, Massachusetts, United States
- University of Michigan University Hospital, Ann Arbor, Michigan, United States
- West Michigan Cancer Center, Kalamazoo, Michigan, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01730950 on ClinicalTrials.govOther trials for Gliosarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07134842A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.University College, London
- ENROLLING BY INVITATIONPHASE1NCT06896110Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade GliomaAndrew P. Groves
- RECRUITINGPHASE1NCT06934889Study of ABBV-637 or ABBV-155 With ERAS-801 for People With GlioblastomaMemorial Sloan Kettering Cancer Center
- RECRUITINGNCT05756985Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain TissueBaptist Health South Florida
- RECRUITINGPHASE2NCT05864534Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed GlioblastomaNorthwestern University
- RECRUITINGNCT06954636Prognostic Potential of Olfactory Function in Glioblastoma: a Prospective Observational StudySied Kebir
- RECRUITINGPHASE1NCT04991870Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBMM.D. Anderson Cancer Center
- RECRUITINGPHASE1NCT05363826Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®Photolitec LLC